Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Patient-Reported Incident Measure (PRIM) tools for reporting patient safety incidents, Protocol for a scoping review

  • Osorio, Dimelza|||0000-0001-6166-647X
  • Plana, Maria Nieves|||0000-0003-0921-7954
  • Rubio-Valera, Maria|||0000-0003-2856-1697
  • Bolibar i Ribas, Ignasi|||0000-0002-4529-1935
  • Suclupe Obregón, Stefanie|||0000-0002-9532-3931
  • Salas-Gama, Karla|||0000-0003-4845-4899
  • Ferreira-Gonzalez, Ignacio|||0000-0002-1208-5561
  • Muñoz-Miguel, Julio
  • Franco Romero, Maria Teresa
  • Secanell Espluga, Mariona|||0000-0002-6835-2243
  • Soler-Font, Merce|||0000-0002-5224-9030
  • Fernández-Torres, Paula
  • Torres-López, Daniel
  • Almar Garayoa, Adrià
  • Giró Estivill, Adrià
  • Ribera Solé, Aida
  • Fuster-Casanovas, Aïna|||0000-0001-9128-9580
  • Saa Casal, Alba
  • Aisa Castillo, Alex
  • Cano Velasco, Alex
  • Sala-Cunill, Anna|||0000-0002-2178-1067
  • Cruz Antolin, Antoni Jesús
  • González Steinbauer, Cristina
  • Mazo Torre, Cristopher Alan
  • Lopez Torres, Daniel
  • Osorio, Dimelza|||0000-0001-6166-647X
  • Torralba Martinez, Elena
  • Devilleneuve, Emilien Amar
  • Gómez, Gonzalo Casans
  • Martínez Pérez, Jesús
  • De Las Heras, Jesús Ruiz
  • Salvador Lodosa, Julia
  • Muñoz-Miguel, Julio
  • Torres Prieto, Magora
  • Del Mar Pina Cobos, Maria
  • Plana, Maria Nieves|||0000-0003-0921-7954
  • Rubio Valera, Maria
  • Franco Romero, Maria Teresa
  • Aguayo Alvarez, Marta
  • Soler-Font, Merce|||0000-0002-5224-9030
  • Urrea Ayala, Mireia|||0000-0002-9271-7468
  • Lopez García, Noemí
  • Viñas, Núria Castany
  • Efrain Pantoja Bustillos, Percy
  • Ortí-Lucas, Rafael M.|||0000-0003-2211-7413
  • Martín Campos, Roser
  • Romea Lecumberri, Soledad
  • Suclupe Obregón, Stefanie|||0000-0002-9532-3931
  • Malgrat Caballero, Susana
  • Quirós Gonzalez, Víctor
  • Valls-Comamala, Victòria
Introduction Patient safety incidents during healthcare cause a high burden and mortality, but many go unreported. Involving patients and caregivers in the identification and reporting of safety incidents would add value to the current incident reporting systems used by health professionals. Identifying and analysing patient safety incidents is essential to prevent future events, allowing organisations to apply a learning-from-error approach and to implement improvement plans. Patient-Reported Incident Measures are tools for patients and caregivers to report safety issues related to their healthcare. In accordance with WHO's patient safety taxonomy, the term patient safety incidents is used throughout this protocol to encompass events that do and do not reach the patient, including what are commonly referred to as near misses and adverse events. We aim to identify and describe the published literature about tools for patients or caregivers to report patient safety incidents in healthcare. Methods and analysis We will conduct a scoping review. We have developed inclusion criteria using the PCC (population, concept and context) format, where population includes adult patients or caregivers; concept refers to documents describing formal tools used to report patient safety incidents; and context includes any healthcare setting, such as hospitals or mental health centres, during or immediately after care. The scoping review will be reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews guidelines. Evidence sources include primary research, systematic reviews, meta-analyses, conference abstracts, letters, guidelines, as well as policy documents, reports, blogs and websites, without language restriction. An initial database search in Medline, Embase, CINAHL, and Cochrane Library from database inception up to June 2023 identified 4500 initial citations, of which 4103 were selected for evaluation after duplicates were removed. We will supplement the search by checking the reference lists of included studies for additional sources of evidence and an additional search in Google to identify non-peer-reviewed documents. This initial search will be updated before completing the review. We will use a self-created data collection form for data extraction and perform a narrative synthesis to integrate and summarise the review findings. We will describe the general characteristics of the tool: setting, scope, format, content, type of patient safety incident and severity, the moment of notification, relation to patient safety incident reporting and learning systems, development process, testing, validation, or piloting, among other characteristics. As a result of this scoping review, we intend to provide an index of patient/caregiver-reported safety notification tools and a list of descriptive or evaluation studies. Ethics and dissemination We will only use published data. Approval from the human research ethics committee is not required. The results of this scoping review will be submitted for publication in an international peer-reviewed journal and scientific meetings. Findings will also be disseminated through digital science platforms and academic social media.
Repisalud
Publicación Artículo científico (JournalArticle)

Quantitative HDL Proteomics Identifies Peroxiredoxin-6 as a Biomarker of Human Abdominal Aortic Aneurysm

  • Burillo, Elena
  • Jorge, Inmaculada
  • Martinez-Lopez, Diego
  • Camafeita, Emilio
  • Miguel Blanco-Colio, Luis
  • Trevisan-Herraz, Marco
  • Ezkurdia, Iakes
  • Egido, Jesus
  • Michel, Jean-Baptiste
  • Meilhac, Olivier
  • Vazquez, Jesus
  • Luis Martin-Ventura, Jose
High-density lipoproteins (HDLs) are complex protein and lipid assemblies whose composition is known to change in diverse pathological situations. Analysis of the HDL proteome can thus provide insight into the main mechanisms underlying abdominal aortic aneurysm (AAA) and potentially detect novel systemic biomarkers. We performed a multiplexed quantitative proteomics analysis of HDLs isolated from plasma of AAA patients (N = 14) and control study participants (N = 7). Validation was performed by western-blot (HDL), immunohistochemistry (tissue), and ELISA (plasma). HDL from AAA patients showed elevated expression of peroxiredoxin-6 (PRDX6), HLA class I histocompatibility antigen (HLA-I), retinol-binding protein 4, and paraoxonase/arylesterase 1 (PON1), whereas alpha-2 macroglobulin and C4b-binding protein were decreased. The main pathways associated with HDL alterations in AAA were oxidative stress and immune-inflammatory responses. In AAA tissue, PRDX6 colocalized with neutrophils, vascular smooth muscle cells, and lipid oxidation. Moreover, plasma PRDX6 was higher in AAA (N = 47) than in controls (N = 27), reflecting increased systemic oxidative stress. Finally, a positive correlation was recorded between PRDX6 and AAA diameter. The analysis of the HDL proteome demonstrates that redox imbalance is a major mechanism in AAA, identifying the antioxidant PRDX6 as a novel systemic biomarker of AAA.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Development of a Submillimetric GNSS-Based Distance Meter for Length Metrology

  • García-Asenjo Villamayor, Luis|||0000-0001-6535-2216
  • Baselga Moreno, Sergio|||0000-0002-0492-4003
  • Atkins, Chris
  • Garrigues Talens, Pascual
[EN] Absolute distance determination in the open air with an uncertainty of a few tenths of a millimetre is increasingly required in many applications that involve high precision geodetic metrology. No matter the technique used to measure, the resulting distances must be proven consistent with the unit of length (SI-metre) as realized in the outdoor facilities traditionally used in length metrology, which are also known as calibration baselines of reference. The current calibration baselines of reference have distances in the range of 10 to 1000 m, but at present there is no solution on the market to provide distances with submillimetric precision in that range. Consequently, new techniques such as multi-wave interferometry, two-wave laser telemeters or laser trackers are being developed. A possible alternative to those sophisticated and expensive techniques is the use of widely used Global Navigation Satellite Systems (GNSS) in order to provide a GNSS-Based Distance Meter (GBDM). The use of a GBDM as a potential technique for length metrology has been thoroughly analysed in several European research projects by using the state-of-the-art geodetic software, such as Bernese 5.2, but no definite conclusions have been drawn and some metrological questions are considered still open. In this paper, we describe a dedicated approach to build up a submillimetric GBDM able to be applied in the current calibration baselines of reference, as well as possible methods to cope with the multipath error of the GNSS signals which is the major limitation for the practical uptaking of the technique in metrology. The accuracy of the proposed approach has been tested following the length metrology standards in four experiments carried out in the Universitat Politecnica de Valencia (UPV). The results demonstrate that the proposed GBDM can provide an accuracy of a few tenths of a millimetre in the current calibration baselines of reference, This work was partly performed within the 18SIB01 GeoMetre project of the European Metrology Programme for Innovation and Research (EMPIR). This project has received funding from the EMPIR programme co-financed by the Participating States and from the European Union's Horizon 2020 research and innovation programme. This research was also partly funded by the Spanish Ministry of Education, Culture and Sports (PRX17/00371).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Trimethylamine-N-Oxide (TMAO) predicts cardiovascular mortality in peripheral artery disease

  • Roncal Mancho, Carmen
  • Martínez Aguilar, Esther
  • Orbe, Josune
  • Ravassa, Susana
  • Fernández-Montero, Alejandro
  • Saenz-Pipaon, Goren
  • Ugarte, Ana
  • Estella-Hermoso de Mendoza, Ander
  • Rodríguez, José Antonio
  • Fernández Alonso, Sebastián
  • Fernández Alonso, Leopoldo
  • Oyarzabal, Julen
  • Páramo, José A.
Peripheral artery disease (PAD) is a major cause of acute and chronic illness, with extremely poor prognosis that remains underdiagnosed and undertreated. Trimethylamine-N-Oxide (TMAO), a gut derived metabolite, has been associated with atherosclerotic burden. We determined plasma levels of TMAO by mass spectrometry and evaluated their association with PAD severity and prognosis. 262 symptomatic PAD patients (mean age 70 years, 87% men) categorized in intermittent claudication (IC, n = 147) and critical limb ischemia (CLI, n = 115) were followed-up for a mean average of 4 years (min 1-max 102 months). TMAO levels were increased in CLI compared to IC (P < 0.001). Receiver operating characteristic (ROC) curves for severity (CLI) rendered a cutoff of 2.26 µmol/L for TMAO (62% sensitivity, 76% specificity). Patients with TMAO > 2.26 µmol/L exhibited higher risk of cardiovascular death (subhazard ratios ≥2, P < 0.05) that remained significant after adjustment for confounding factors. TMAO levels were associated to disease severity and CV-mortality in our cohort, suggesting an improvement of PAD prognosis with the measurement of TMAO. Overall, our results indicate that the intestinal bacterial function, together with the activity of key hepatic enzymes for TMA oxidation (FMO3) and renal function, should be considered when designing therapeutic strategies to control gut-derived metabolites in vascular patients., This work was supported by the Foundation for Applied Medical Research, Universidad de Navarra (Spain); European Fund for Economic and Regional Development (FEDER) funds [FIS PI18/01195], Ministry of Economy and Competitiveness, Institute of Health Carlos III, [CIBER-CV (CB16/11/00371)]. Patrimonio Praga (Mexico) and Virto Group (Spain).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Urinary extracellular vesicles for diabetic kidney disease diagnosis

  • Saenz-Pipaon, Goren
  • Echeverría Ilundáin, Saioa
  • Orbe, Josune
  • Roncal Mancho, Carmen
Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in developed countries, affecting more than 40% of diabetes mellitus (DM) patients. DKD pathogenesis is multifactorial leading to a clinical presentation characterized by proteinuria, hypertension, and a gradual reduction in kidney function, accompanied by a high incidence of cardiovascular (CV) events and mortality. Unlike other diabetes-related complications, DKD prevalence has failed to decline over the past 30 years, becoming a growing socioeconomic burden. Treatments controlling glucose levels, albuminuria and blood pressure may slow down DKD evolution and reduce CV events, but are not able to completely halt its progression. Moreover, one in five patients with diabetes develop DKD in the absence of albuminuria, and in others nephropathy goes unrecognized at the time of diagnosis, urging to find novel noninvasive and more precise early diagnosis and prognosis biomarkers and therapeutic targets for these patient subgroups. Extracellular vesicles (EVs), especially urinary (u)EVs, have emerged as an alternative for this purpose, as changes in their numbers and composition have been reported in clinical conditions involving DM and renal diseases. In this review, we will summarize the current knowledge on the role of (u)EVs in DKD., This research was funded by “Instituto de Salud Carlos III-FEDER,” Fondo de Investigaciones Sanitarias [PI18/01195] and CIBERCV (CB16/11/00371). G.S.-P. was funded with a PhD scholarship from The Foundation for Applied Medical Research, Universidad de Navarra (Spain).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Reduced high-density lipoprotein cholesterol: a valuable, independent prognostic marker in peripheral arterial disease

  • Martínez Aguilar, Esther
  • Orbe, Josune
  • Fernández-Montero, Alejandro
  • Fernández Alonso, Sebastián
  • Rodríguez, José Antonio
  • Fernández Alonso, Leopoldo
  • Páramo, José A.
  • Roncal Mancho, Carmen
Objective The prognosis of patients with peripheral arterial disease (PAD) is characterized by an exceptionally high risk for myocardial infarction, ischemic stroke, and death; however, studies in search of new prognostic biomarkers in PAD are scarce. Even though low levels of high-density lipoprotein cholesterol (HDL-C) have been associated with higher risk of cardiovascular (CV) complications and death in different atherosclerotic diseases, recent epidemiologic studies have challenged its prognostic utility. The aim of this study was to test the predictive value of HDL-C as a risk factor for ischemic events or death in symptomatic PAD patients. Methods Clinical and demographic parameters of 254 symptomatic PAD patients were recorded. Amputation, ischemic coronary disease, cerebrovascular disease, and all-cause mortality were recorded during a mean follow-up of 2.7 years. Results Multivariate analyses showed that disease severity (critical limb ischemia) was significantly reduced in patients with normal HDL-C levels compared with the group with low HDL-C levels (multivariate analysis odds ratio, 0.09; 95% confidence interval [CI], 0.03-0.24). A decreased risk for mortality (hazard ratio, 0.46; 95% CI, 0.21-0.99) and major adverse CV events (hazard ratio, 0.38; 95% CI, 0.16-0.86) was also found in patients with normal vs reduced levels of HDL-C in both Cox proportional hazards models and Kaplan-Meier estimates, after adjustment for confounding factors. Conclusions Reduced HDL-C levels were significantly associated with higher risk for development of CV complications as well as with mortality in PAD patients. These findings highlight the usefulness of this simple test for early identification of PAD patients at high risk for development of major CV events., This work was supported by the Foundation for Applied Medical Research, University of Navarra (Pamplona, Spain); European Fund for Economic and Regional Development (FEDER) funds (FIS PI14/01152); and the Ministry of Economy and Competitiveness, Institute of Health Carlos III (RIC [RD12/ 0042/0009] and CIBER-CV [CB16/11/00371]).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Lipocalin-2 and calprotectin potential prognosis biomarkers in peripheral arterial disease

  • Saenz-Pipaon, Goren
  • Ravassa, Susana
  • Larsen, Katrine L.
  • Martínez Aguilar, Esther
  • Orbe, Josune
  • Rodríguez, José Antonio
  • Fernández Alonso, Leopoldo
  • González, Arantxa
  • Martín-Ventura, José Luis
  • Páramo, José A.
  • Lindholt, Jes S.
  • Roncal Mancho, Carmen
Objective: Peripheral arterial disease (PAD) is the most prevalent cardiovascular (CV) condition globally. Despite the high CV risk of PAD patients, no reliable predictors of adverse clinical evolution are yet available. In this regard, previous transcriptomic analyses revealed increased expression of calprotectin (S100A8/A9) and lipocalin-2 (LCN2) in circulating extracellular vesicles (EVs) of patients with PAD. The aim of this study was to determine the prognostic value of LCN2 and calprotectin for CV risk assessment in PAD. Methods: LCN2 and the S100A9 subunit of calprotectin were examined in human femoral plaques by immunohistochemistry and qPCR. LCN2 and calprotectin were determined by ELISA in PAD (CHN cohort, n ¼ 331, Fontaine IIeIV, serum), and PAD diagnosed by population based screening (VIVA trial, n ¼ 413, the majority Fontaine 0eI, plasma). Patients were followed up for a mean of four years, recording the primary outcomes; CV death or amputation in the CHN cohort and CV death or major lower limb events (MALE) in the VIVA population. Secondary outcomes were all cause death or amputation, and all cause death or MALE, respectively. Results: LCN2 and S100A9 were detected in human plaques in regions rich in inflammatory cells. LCN2 and calprotectin levels were 70% and 64% lower in plasma than in serum. In the CHN cohort, high serum levels of LCN2 and calprotectin increased the risk of primary and secondary outcomes 5.6 fold (p < .001) and 1.8 fold (p ¼ .034), respectively, after covariable adjustment. Similarly, elevated plasma levels of LCN2 and calprotectin increased by three fold the risk of primary and secondary outcomes (p < .001) in the VIVA cohort. Moreover, addition of the combined variable to basal models, considering clinically relevant risk factors, improved reclassification for the primary outcome in both cohorts (p .024). Conclusion: Combined assessment of the inflammatory biomarkers LCN2 and calprotectin might be useful for risk stratification in advanced and early PAD., The Foundation for Applied Medical Research, Universidad de Navarra (Spain); Ministry of Science and Innovation, Institute of Health Carlos III, co-funded by the European Fund for Economic and Regional Development (FEDER) [PI18/01195], Ministry of Science and Innovation, Institute of Health Carlos III [CB16/11/00371 and CB16/11/00483] and VIRTO group.